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Currently, approximately 50,000 hematopoietic stem cell
transplantations (HSCTs) are performed annually worldwide,
and data suggest these numbers will continue to rise steadily
[1,2]. These facts have prompted investigation into the scale
of the current HSCT provider workforce, leading to the
conclusion that current trends in the ﬁeld will likely lead to
an insufﬁcient physician workforce by the year 2020 [3]. In
2009, Gajewski et al. calculated that approximately 1115
physicians were performing HSCTs and that 2226 physicians
will be required by the year 2020 tomeet the ever-increasing
demand [3]. A trend in recent years has been for similar
disparities between provider need and provider availability
to be addressed by midlevel providers, including nurse
practitioners and physician assistants, both in the inpatient
and ambulatory settings. With resident physicians’ (i.e.,
house staff’s) duty hours becoming progressively restricted
and an impending deﬁcit in primary care pushing residency
programs toward more ambulatory medical training, it
might seem logical for the ﬁeld of HSCT to likewise move
toward midlevel providers to provide coverage for HSCT
patients. However, although this scenario likely provides safe
and satisfactory patient care while easing demands on HSCT
physician providers, it does not seem to be in the best
interest of resident physician education or the ﬁeld of HSCT
as a whole.
MIDLEVEL PROVIDERS AND HOUSE STAFF
INVOLVEMENT
The ﬁeld of HSCT has shown remarkable advancement
since its instatement with the ﬁrst transplantation in 1968.
Increasingly more transplantations are performed using
“alternative” donor cell sources, including matched or mis-
matched unrelated donors, partially matched related donors,
and umbilical cord blood, and for an increasing number of
indications [4]. This has created, and will likely continue to
create, more diversity in the HSCT patient population.
Furthermore, reduced-intensity conditioning regimens and
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for older patients and those with more medical comorbid-
ities to be considered for HSCT [2,5].
The role of midlevel providers has evolved such that they
are now essential members of multidisciplinary medical
teams, particularly in the ﬁeld of HSCT. These providers could
create a synergistic clinical environment when paired with,
rather than being used in place of, house staff. Midlevel
providers could ensure the execution of HSCT standard
practice and bring to light medical and psychosocial issues
unique to HSCT. House staff could then draw on other aspects
of their training to maintain evidence-based workup and
management of comorbid medical conditions. This envi-
ronment would not only provide well-rounded patient care,
but also create a unique avenue for resident education. These
midlevel providers would inevitably assist with informal
teaching, but could also be asked to conduct didactic
teaching for house staff about topics speciﬁc to their expe-
rience with the transplantation population.CAREER DEVELOPMENT
In addition to possible beneﬁts to transplantation patients
and teams, allowing resident physicians to participate in the
care of HSCT patients beneﬁts resident education and the
transplantation ﬁeld as a whole. Many residency programs
currently allow residents to participate in the care of patients
with hematologic malignancies, and it seems only ﬁtting that
residents should be given the opportunity to witness such
an important outcome of hematologic malignancies. Not
only would this afford the opportunity to learn about the
transplantation process itself, but HSCT recipients provide
myriad educational opportunities regarding management of
transplantation-related issues. Furthermore, the increasing
number of patients undergoing HSCT will likely create larger
numbers of patients surviving post-transplantation and
interacting with physicians in other ﬁelds of medicine.
Therefore, increased familiarity with the process and
complications of HSCT could positively impact the care these
patients receive from providers in other ﬁelds.
Another beneﬁt afforded residents by allowing their
participation in the care of these patients is that of career
development. In 1998, Ballen et al. examined resident
physician participation in the care of HSCT patients in North
American institutions and revealed that 93% of the 152
surveyed institutions had some involvement of residents
with HSCT patients, but nearly one-third were only involved
by way of emergency coverage [6]. Beginning in the 2012
cycle of fellowship application, the medical specialties match
program has delayed the timeline for fellowship application
until later in residency. Therefore, direct exposure to theSociety for Blood and Marrow Transplantation.
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plantation physicians may facilitate interest in the ﬁelds of
hematology and transplantation medicine, and there is now
more time before fellowship application during which
residents’ plans could be inﬂuenced. In 2012, Majhail et al.
noted that efforts to recruit medical students and residents
has thus far been limited, and reiterated that one of the
goals of the National Marrow Donor Program Workforce
Working Group is to identify and remove barriers to HSCT
physician recruitment and training [7]. By choosing mid-
level providers in place of, rather than in addition to, resi-
dent physicians to provide patient care for patients
undergoing stem cell transplantations, we lose direct access
to an essential recruiting pool. Furthermore, given a pre-
dicted shortage of transplantation physicians by the year
2020, it does not seem that the ﬁeld can afford to lose this
opportunity [3].
IMPACT ON CLINICAL OUTCOME
Certainly when considering such a complex patient
population, it is essential to address the question of safety.
Loberiza et al. [8] explored this question in a study of
transplantation centere and provider-related factors. In this
study, patients who underwent allogeneic HSCT were found
to have a minimally signiﬁcant odds ratio (OR) for 100-day
mortality when treated at a center at whichmedical students
and/or residents, but not hematology-oncology or stem cell
fellows, cover for the transplantation patients (OR, 2.35) [8].
However, this was less signiﬁcant for both hospitals with
medical school afﬁliations characterized by fellows only
(OR, 1.43) and by medical students, residents, and fellows
(OR, 1.43). There were less-signiﬁcant ORs for the same
scenarios for autologous transplantations (OR, 1.79, 1.27, and
1.08, respectively) [8]. That being said, none of these provider
characteristics showed any signiﬁcant association with
mortality at 1 year post-transplant.
This same author reviewed the center effect for HSCT
patients in a preceding article from 2003 [9]. This review did
reveal a relationship between patient volume and mortality
in the HSCT setting, generally concluding that patients who
receive allogeneic transplantations at high-volume centers
have decreased risk of treatment-related mortality, treat-
ment failure, and mortality, although the same could not be
said for autologous transplantations [9]. Given that many
high-volume transplantation centers are academic centers as
well, it does not seem possible to completely separate beneﬁt
related to treatment at a high-volume center from all
provider-related factors, including those related to house
staff.CHALLENGES
When considering integration, or reintegration, of house
staff into the patient care of HSCT patients, one cannot ignore
the challenges of using house staff in this role. The major
impediment is that of house staff education, both didactic
teaching about evidence-based HSCT practice and teaching
about the commonplace transplantation-speciﬁc issues they
would be called to manage. This seems particularly onerous
in the era of duty-hour restrictions that limit house staff
to 80 hours per week. These duty-hour limitations have
required global revisions in call practices, and consequently,
most internal medicine and hematology/oncology programs
have instituted a system of day and night shifts, and HSCT
services need not deviate from this approach. However,
the issue of teaching remains challenging within these
constraints.
Integration of internal medicine house staff into the care
of patients undergoing HSCT could serve as a solution to
several impending challenges, including management of
increasingly complicated HSCT patients, education of resi-
dent physicians about the process and complications of
HSCT, and the mentorship and recruitment of future trans-
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